Protection of rosiglitazone against renal interstitial lesion and its mechanism

National Medical Journal of China

Volumn 85, Issue 23, 2005, Pages 1618-1624

  Lin, Qin ^a   Gu, Yong ^b   Ma, Ji ^b   Lin, Shan Yan ^b  

^a FUDAN UNIVERSITY   (China)

^b NONE

Author keywords

Kidney diseases; Rosiglitazone; Transforming growth factor beta

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; MESSENGER RNA; OSTEOGENIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN ANTIBODY; ROSIGLITAZONE; SMAD6 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY HOMOGENATE; MACROPHAGE; MALE; MICROSCOPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URETER OBSTRUCTION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; HYPOGLYCEMIC AGENTS; MALE; NEPHRITIS, INTERSTITIAL; NEPHROSCLEROSIS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA; URETERAL OBSTRUCTION;

EID: 23844512482     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med, 2001, 52: 239-257.
2. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med, 2002, 53: 409-435.
3. Kon K, Ikejima K, Hirose M, et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun, 2002, 291: 55-61.
4. Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology, 2002, 122: 1924-1940.
5. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferation-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2002, 106: 3126-3 32.
6. Ma LJ, Marcantoni C, Linton MF, et al. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerudosclerosis in rats. Kidney Int, 2001, 59: 1899-1910.
7. Zheng F, Fomoni A, Eliot SJ, et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol, 2002, 282: F639-648.
8. Guan Y, Zhang Y, Schneider A, et al. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol, 2001, 281: F1036-1046.
9. Shappell SB, Gurpinar T, Lechago J, et al. Chronic obstructive uropathy in severe combined immumodeficient (SCID) mice: lymphocyte infiltration is not required for progressive tubulointerstitial injury. J Am Soc Nephrol, 1998, 9: 1008-1017.
10. Hogan BLM. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev, 1996, 10: 1580-1594.
11. Liu YP, Deng JX. Intracellular signaling proteins of TGF-β: SMAD proteins family. Progress Biomechanism, 2000, 20: 8-12.
12. Almanzar MM, Frazier KS, Dube PH, et al. Osteogenic protein-1 mRNA expression is selectively modulated after acute ischemic renal injury. J Am Soc Nephrol, 1998, 9: 1456-1463.
13. Hruska K, Guo G, Wozniak M, et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol, 2000, 280: F130-F143.
14. Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenctic protein-7 in diabetic nephropathy. J Am Soc Nephrol, 2001, 12: 2392-2399.
15. Morrissey J, Hruska K, Guo G, et al. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol, 2002, 13: S14-S21.
16. Dorai H, Vukicecic S, Sampath TK. Bone morphogenetic protein-7 (osteogenic protein -1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic. J Cell Physiol, 2000, 184: 37-45.
17. Imamura T, Takase M, Nishihara A, et al. Smad6 inhibits signaling by the TGF-beta superfamily. Nature, 1997, 389: 622-626.
18. Dorai H, Shepard A, Ozkaynak E, et al. The 5′ flanking region of the human bone morphogenetic protein-7 gene. Biochem Biophys Res Commun, 2001, 282: 823-831.
19. Duncan MR, Frazier KS, Abramson S, et al. Connective tissue growth factor mediates transforming growth factor bela-induced collagen sythesis: down-regulation by Camp. FASEG J, 1999, 13: 1774-1788.
20. Waltz DA, Natkin LR, Fujita RM, et al. Plasmin and PAI-1 promote cellular motility by regulating the interaction between urokinase receptor and vitronectin. J Clin Invest, 1997, 100: 58-67.